Vertex Pharmaceuticals (VRTX) return on equity (ROE)

Return on equity · fiscal 2025
21.2%

Vertex Pharmaceuticals (VRTX) earned a return on equity of 21.2% in fiscal 2025 (the year ended December 31, 2025). That is 24.4 percentage points higher than the -3.3% of fiscal 2024. Figures as of 17 Nov 2026, 20:46 UTC, from the company's filings with the SEC and Yahoo Finance.

Key facts

Return on equity, fiscal 2025
21.2%
Change on fiscal 2024
+24.4 pts
Highest on record
47.3%fiscal 2018
Lowest on record
-192.5%fiscal 2008
Fiscal years on record
182008–2025

Figures as of . Older fiscal years come from the company's filings with the SEC, recent ones from Yahoo Finance. Figures, not advice.

Vertex Pharmaceuticals return on equity (ROE), in more detail

Across the 18 fiscal years on record (2008–2025), the highest was 47.3% in fiscal 2018 and the lowest -192.5% in fiscal 2008. The fiscal 2025 figure is higher than in 76% of the 17 earlier fiscal years on record, whose median is -3.3%.

History · 18 fiscal years

Return on equity by fiscal year

Vertex Pharmaceuticals return on equity (ROE), year by year

Vertex Pharmaceuticals (VRTX) return on equity (ROE) by fiscal year
Fiscal yearReturn on equityChangeYear ended
202521.2% 24.4 pts up
2024-3.3% 23.9 pts down
202320.6% 3.3 pts down
202223.9% 0.7 pts up
202123.2% 8.0 pts down
202031.2% 11.9 pts up
201919.3% 27.9 pts down
201847.3% 34.3 pts up
201713.0% 22.7 pts up
2016-9.7% 49.5 pts up
2015-59.2% 9.5 pts up
2014-68.7% 35.9 pts down
2013-32.8% 22.1 pts down
2012-10.7% 14.5 pts down
20113.8% 153.5 pts up
2010-149.7% 91.2 pts down
2009-58.6% 133.9 pts up
2008-192.5%—

Change is on the fiscal year before, in percentage points; a dash means that year is not on record. A dash anywhere else means the figure was not reported or cannot be computed — it is never filled in.

Method

How it is calculated

Return on equity is net income divided by shareholders' equity at the fiscal year-end; it is left blank when equity is negative.

How to read it

It is the profit earned on the owners' capital — above about 15% is strong, though heavy debt or large buybacks can inflate it.

Return on equity at health care companies of similar size

Return on equity of Vertex Pharmaceuticals and comparable companies
CompanyReturn on equityFiscal year
Pfizer PFE9.0%2025
Danaher DHR6.9%2025
Intuitive Surgical ISRG16.0%2025
Vertex Pharmaceuticals VRTX21.2%2025
Medtronic MDT9.7%2026
Bristol-Myers Squibb BMY38.2%2025

The latest fiscal year on record for each company, in the currency it reports in. Fiscal years end at different times of year.

More on VRTX

Vertex Pharmaceuticals, figure by figure

Vertex Pharmaceuticals (VRTX) overview: price, valuation and scorecardAll health care companies by market value

Vertex Pharmaceuticals return on equity (ROE): questions and answers

What is Vertex Pharmaceuticals's return on equity?

Vertex Pharmaceuticals (VRTX) earned a return on equity of 21.2% in fiscal 2025 (the year ended December 31, 2025). That is 24.4 percentage points higher than the -3.3% of fiscal 2024.

Is Vertex Pharmaceuticals's return on equity high or low compared with its own history?

The fiscal 2025 figure is higher than in 76% of the 17 earlier fiscal years on record, whose median is -3.3%.

What are the highest and lowest return on equity figures on record for Vertex Pharmaceuticals?

Across the 18 fiscal years on record (2008–2025), the highest was 47.3% in fiscal 2018 and the lowest -192.5% in fiscal 2008.

How is Vertex Pharmaceuticals's return on equity calculated?

Return on equity is net income divided by shareholders' equity at the fiscal year-end; it is left blank when equity is negative.

Fiscal years are named for the calendar year they end in.

Cite this page

Funkfolio, “Vertex Pharmaceuticals (VRTX) return on equity (ROE)”, data as of 17 November 2026. https://funkfolio.com/stock/VRTX/roe

Underlying data: the company's filings with the SEC and Yahoo Finance.